Laryngeal cancer affects the voice box. This guide covers assessment, treatment conversations, rehabilitation and source funding. NHS definition.
- Glottic, supraglottic and subglottic cancers involve different voice-box regions.
- Persistent hoarseness needs assessment; symptoms differ by site.
- Specialist examination and tissue sampling establish the diagnosis.
- After total laryngectomy, breathing is through a permanent neck stoma.
- Discuss breathing, swallowing, communication, nutrition and rehabilitation with the team.
Table of contents
- Evidence summary
- Voice-box anatomy
- Risks and causes
- Symptoms
- Tests and staging
- Treatment choices
- Laryngectomy and airway safety
- Treatment side effects
- Swallowing and nutrition
- Urgent care and follow-up
- Research and coverage limits
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Diagnosis | Anatomy and pathology sources. | Disclosures below. | No personal staging algorithm. |
| Treatment | Attributed care roles and US regulatory status. | Sponsored efficacy excluded. | No independent product ranking. |
| Permanent airway | Dated CUH leaflet. | Provider accounts below. | Confirm the operation and emergency plan. |
| Support | Selected safety and rehabilitation sources. | Allocations unresolved. | Discuss function and follow-up. |
Voice-box anatomy
The glottis contains true vocal cords; supraglottis lies above and subglottis below. Most laryngeal cancers arise from squamous lining cells. NCI laryngeal anatomy.
The April 2026 CAP laryngeal reporting protocol separates laryngeal subsites and records tissue findings, margins and lymph nodes. It uses AJCC 8. Rare neuroendocrine, salivary and other histologies need separate assessment. CAP current reporting scope.
Ask the team to write down the exact primary site, tissue type and staging edition. Keep a copy of the report for later care or a second opinion.
Risks and causes
Smoking and drinking substantial amounts of alcohol are important laryngeal cancer risks. The cause is not always clear, and anyone can develop the disease. A risk factor changes likelihood; it cannot prove why a particular tumour developed or exclude disease in someone without that exposure. Discuss tobacco cessation and alcohol support with a clinician, without delaying investigation of a current symptom. NHS risk account.
Head-and-neck cancers form several anatomical disease groups. The importance of viral infection and other exposures differs by site. Do not transfer the HPV-associated oropharyngeal framework automatically to a voice-box tumour. Ask whether a proposed test has a specific purpose for the actual pathology. NCI site-specific risk context.
A prevention discussion is different from treating a diagnosed tumour. Explain previous cancer treatment and relevant exposures honestly; the purpose is to inform care.
Symptoms
Persistent hoarseness or a changed voice, a neck lump, painful or difficult swallowing, and breathing difficulty warrant clinical assessment. Ear pain or unexplained weight loss can also occur. These symptoms often have other causes. A growing lump or persistent voice change merits reassessment. Report progression and impaired function. NHS symptoms and assessment.
Vocal-cord cancer may cause hoarseness relatively early. A supraglottic tumour can instead present with throat or swallowing pain, referred ear pain or a neck node. One familiar symptom list cannot predict every subsite. NCI subsite presentation.
Record symptoms and progression for the appointment. Confirm who will explain results and when.
Tests and staging
Assessment can involve a thin camera passed through the nose or mouth to inspect the throat and voice box, with tissue sampling to confirm the diagnosis. A neck lump may be sampled with a needle. The specialist selects appropriate scans. Vocal-cord movement may also be assessed. Confirm result timing and responsibility. NHS investigation pathway.
The stage describes local tumour extent, nodes and distant disease. Clinical and pathological assessment contribute different information. CAP AJCC 8 framework.
At the results visit, ask what is confirmed, what remains uncertain and whether additional tests would change the proposed plan. An isolated scan finding or marker does not replace the complete interpretation.
Treatment choices
The head-and-neck team selects treatment around tumour site, type, extent and health. Options include surgery, radiation and selected systemic medicines; some are combined. Surgery may include neck nodes. Discuss goals and recovery. NHS treatment roles.
Partial laryngectomy removes part of the voice box; total laryngectomy removes it all. Ask separately about preserving anatomy and useful function. NCI surgical roles.
The June 12, 2025 FDA decision includes perioperative pembrolizumab for selected adults with resectable locally advanced head-and-neck squamous cancer meeting its PD-L1 criterion. This is a bounded US regulatory indication, not an instruction for every laryngeal cancer. Local access, current label, pathology and health determine suitability. FDA selected status.
Manufacturer-applicant outcomes are excluded from the independent verdict. Older summary drug menus are not a complete current local treatment list. Ask about alternatives and the likely practical consequences before consenting.
Laryngectomy and airway safety
After a total laryngectomy, the windpipe opens through a permanent neck stoma and is disconnected from the nose and mouth. Breathing is through that stoma. Tell emergency responders this neck-breathing anatomy: ordinary mouth-to-mouth is ineffective. Carry airway information and obtain the team’s plan. CUH permanent-airway explanation.
Voice prostheses, electrolarynx or oesophageal speech require specialist selection/training. Ask the ENT or speech team about prosthesis leakage or displacement. CUH speech and prosthesis context.
Ask the surgical team to write down the exact operation and emergency instructions.
Treatment side effects
Radiation effects depend on the body area treated. Head-and-neck exposure can cause mouth or throat problems, taste changes and reduced thyroid function, alongside fatigue or skin effects. Some problems develop later or persist. Ask which tissues are in the treatment field and which symptoms need immediate contact or planned monitoring. Do not assume a new problem is harmless because it resembles an expected side effect. NCI radiation safety.
Cancer treatment can cause mouth sores, dryness, pain, infection, taste changes and dental problems. Coordinate dental care and mouth-care advice with the treating team. Report pain that interferes with eating or sleep. Before an invasive dental procedure, clarify cancer medicines, healing and bleeding issues. Do not copy a rinse recipe or start a medicine without considering the actual treatment. NCI dated mouth-care context.
Bring the full prescription, nonprescription and supplement list to the oncology pharmacist. Ask how treatment interacts with other illnesses and whom to contact about new symptoms. This article does not supply medicine doses, radiation fractions, stopping rules or a home infection protocol.
Swallowing and nutrition
Food sticking, coughing or choking with intake, a wet voice after swallowing, or breathlessness after meals needs urgent clinical advice. Swallowing problems can lead to dehydration, weight loss or chest infection. Assessment should guide texture and safe intake; a thickener or supplement drink is not automatically suitable for every problem. NHS dysphagia warning.
Speech-and-language support can help communication and swallowing. Ask about rehabilitation after treatment. NHS treatment support; swallowing support.
Ask who coordinates nutrition, medicine administration, emotional support and return to work. Confirm responsibilities and follow-up.
Urgent care and follow-up
Severe breathing difficulty, gasping, choking or inability to get words out requires local emergency help. Do not drive yourself or wait for the cause to be established. Worsening breathlessness that is less severe still needs urgent advice. NHS airway warning.
No diet trend, herb, vitamin or supplement has been proved in the NCI account reviewed here to cure cancer, slow its growth or prevent return. Products can change how cancer medicines work. Show the pharmacist ingredients before adding an extract or high-dose vitamin. Treating a documented deficiency is a separate clinical task. Restrictive diets can make adequate intake harder when swallowing is already affected. NCI supplement boundary.
Keep a survivorship record of the pathology, surgery, radiation and medicines, with responsibility for follow-up and symptoms to report between visits. The schedule is individual. Share the plan with primary and dental care so later changes are interpreted in the context of treatment. NCI follow-up planning.
Keep urgent-contact instructions with the care record.
Research and coverage limits
Treatment trials and supportive-care studies ask different questions. Ask about the comparison care, meaningful patient outcomes, harms, costs and funders before joining research. Experimental treatment is not a promised benefit. Animal and cell findings cannot establish a safe human cancer treatment. NCI research categories.
Institutional finance, individual research roles and trial sponsorship are assessed separately in the map. None alone establishes a page payment or an independently proved treatment benefit.
This guide addresses the common squamous-cancer framework. Rare laryngeal histologies and detailed subsite-specific operations or systemic regimens remain separately unassessed; brief mentions are not complete subtype coverage.
Funding and source roles
Research funding at a glance
38 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NCI laryngeal professional PDQ | PDQ policy; Bonetti supplier-linked research, Truong incomplete declaration. Full page/trial payments unclosed. | United States NCI; international reviewers. | Tier 3 reviewer-linked research; incomplete interests. | C, provisional; named leads/derivation checked. Editorial review does not clear sponsored trials. |
| NCI laryngeal patient PDQ | PDQ policy; Bonetti supplier-linked research, Truong incomplete declaration. Full page/trial payments unclosed. | United States NCI; international reviewers. | Tier 3 reviewer-linked research; incomplete interests. | C, provisional; named leads/derivation checked. Editorial review does not clear sponsored trials. |
| NHS laryngeal definition | Page/contributor/study allocations unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS laryngeal symptoms and breathing warning | Page/contributor/study allocations unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS laryngeal risk explanation | Page/contributor/study allocations unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS laryngeal tests and next steps | Page/contributor/study allocations unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS laryngeal treatment and functional support | Page/contributor/study allocations unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| CAP April 2026 larynx protocol v4.3 | CAP income; Cipriani maker-funded research participation, not personal/protocol fees. Full author/page allocations unclosed. | United States CAP; Northfield, Illinois; international contributors. | Tier 3 author-linked commercial research; incomplete chain. | C, provisional; selected current classification. Service/research interests and study gaps; no efficacy clearance. |
| CUH laryngectomy stoma and voice-prosthesis leaflet | Provider accounts; exact leaflet/contributor/study payments unclosed. | United Kingdom; CUH, Hills Road, Cambridge CB2 0QQ. | Tier 2 dated provider context, provisional. | C, provisional; July 2023 approved leaflet. Print date is not review; service interests remain. |
| Cambridge University Hospitals 2025–26 own annual accounts | Actual 197-page original selected notes 2.1–2.3: NHS England/ICB commissioning, private/overseas patients, research, training, services, rents and capital donations. Report separately describes industry, NIHR and charity research routes. No disease-document allocation inferred. | United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge. Provider route differs from national NHS website. | Tier 3 statutory institutional financial self-report. | B, provisional — actual income notes and selected research passages read. Public accountability improves checking; private, research and service incentives and complete page/author allocations remain. |
| CAP current protocol release register | CAP revenue profile; exact release-page and contributor allocations unclosed. | United States; Northfield, Illinois institution, international laboratory use. | Tier 3 society reporting and service context. | B, provisional — actual release entries read, not all protocols; identity/update source only. |
| CAP 2025 own annual report: selected financial tables | Actual selected table lists proficiency testing, accreditation, publications, membership, education, sponsorship/advertising and investments. Own reporting; protocol allocations unclosed. | United States; headquarters in separate contact row. | Tier 3 mixed service and institutional financial self-report. | B, provisional — selected finances read. Service and professional-advocacy incentives, incomplete allocations remain. |
| CAP current contact and support | Own contact identity; separate annual-report revenue profile. | United States; 325 Waukegan Road, Northfield, Illinois 60093–2750; additional Washington office. | Tier 3 institutional identity self-report. | B, provisional — actual address read; location does not close author or study-chain interests. |
| DEPEND March 6, 2025 original: protocol-author research funding | Actual original names Cipriani data interpretation/review roles and Bristol Myers Squibb/Celgene funding plus Chicago cancer-centre grant P30 CA14599. Sponsor reviewed manuscript. No other individual disclosures for Cipriani in this record; not proof of personal fees or protocol payment. | United States; University of Chicago affiliation/study setting. Complete sponsor ownership, headquarters, contracts and personal income not traced. | Tier 4 manufacturer-funded trial; excluded independent efficacy. | D for independence — direct seller funding. Participation/finance only; no trial benefit, dose or treatment-reduction claim adopted. |
| NCI head-and-neck cancer fact sheet | Page/contributor/study allocations unclosed. | United States; NCI/NIH/HHS. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI native mouth and throat side effects | Page/contributor/study allocations unclosed. | United States; NCI/NIH/HHS. | Tier 2 public clinical context, provisional. | C, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI radiation side effects | Page/contributor/study allocations unclosed. | United States; NCI/NIH/HHS. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI diets and supplements | Page/contributor/study allocations unclosed. | United States; NCI/NIH/HHS. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI follow-up medical care | Page/contributor/study allocations unclosed. | United States; NCI/NIH/HHS. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NCI clinical-trial explanation | Page/contributor/study allocations unclosed. | United States; NCI/NIH/HHS. | Tier 2 public clinical context, provisional. | B, provisional; selected dated body read. Expert education; unclosed interests and simplification limits. |
| NHS swallowing-problem safety | Page/contributor/study allocations unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | C, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| NHS severe breathing warning | Page/contributor/study allocations unclosed. | United Kingdom; national website, not provider-trust finance. | Tier 2 public context, provisional. | B, provisional; actual selected body. Review timing/local-pathway limits remain; no personal regimen. |
| Andrea Bonetti current own biography and clinical-service page | Own biography identifies PDQ membership, Pederzoli clinical-trial/accreditation consultancy since 2024 and current responsibility for EORTC 2129 TREATctDNA. The site offers oncology consultations. Exact remuneration and page allocation are not public here. | Italy; oncology biography identifies Pederzoli Hospital and former Mater Salutis, Legnago roles. Complete service/entity income and beneficial ownership unclosed. | Tier 3 clinical/research identity self-report; financial identity only. | C, provisional — actual own body read. Self-presentation and service interests remain; exact receipts unclosed. No clinical outcomes adopted. |
| EORTC and Menarini TREATctDNA announcement, October 19, 2023 | The joint announcement says Menarini and wholly owned subsidiary Stemline will supply elacestrant for EORTC 2129. It does not document personal fees or PDQ payments. | Belgium and Italy; announcement dateline Brussels/Florence. Complete trial contracts, assay support and supplier/manufacturing jurisdictions unclosed. | Tier 4 manufacturer-supplied trial; excluded independent efficacy. | D for independence — direct product-seller support is documented. Financial-role evidence only; no trial benefit, response, dose or medicine recommendation adopted. |
| EORTC institutional funding model | Actual own page lists institutional, corporate and private donations; study/service fees; industry-funded trials; EU grants and other restricted/unrestricted routes. It states there is no direct government subsidy. Its chart and narrative periods differ; no current complete audited ledger inferred. | Belgium; EORTC is established under Belgian law. Headquarters in the separate contact row. | Tier 3 institution with mixed commercial and noncommercial funding. | B, provisional — explicit routes improve transparency; fundraising incentives, dated components and exact project/reviewer allocation gaps remain. |
| EORTC current institutional contact | Own institutional identity source; mixed revenue routes documented separately. | Belgium; Avenue Emmanuel Mounier 83/11, 1200 Brussels. International clinical research. | Tier 3 institutional identity self-report. | B, provisional — actual address read; location does not establish independent evidence or identify all trial sites. |
| Menarini current headquarters and company registration | Own company registration. Beneficial ownership and individual remuneration unverified. | Italy; Via Sette Santi 1, 50131 Firenze, Florence. Headquarters is not the complete manufacturing chain. | Tier 4 pharmaceutical manufacturer identity self-report. | D for independence — direct pharmaceutical interests. Identity only; backers and allocations unclosed. |
| Minh Tam Truong ASTRO 2024 presenter disclosure | Actual page identifies Boston Medical Center/Boston University employment and no ownership/leadership interests. The compensation field contains an incomplete placeholder and is not interpreted as no compensation. Full income and PDQ payments remain unclosed. | United States; Boston, Massachusetts affiliations. Exact activity revenues and other backer jurisdictions unclosed. | Tier 3 incomplete author financial self-report. | C, provisional — actual identity and field contents read; malformed compensation disclosure prevents financial clearance. No event treatment claims adopted. |
| ASTRO 2022 head-and-neck committee disclosures | Actual three-page original lists Truong’s Boston Medical Center and Veterans Affairs roles plus American Board of Radiology travel expenses. This is scoped to the 2022 activity and previous year; other faculty’s commercial interests are not attributed to her. | United States; named Boston affiliations. Full ASTRO/ABR revenue, travel amounts and present reviewer income not traced. | Tier 3 dated activity financial self-report. | B, provisional — explicit historical disclosure assists provenance; it does not clear later compensation or assign payment to a May 2025 PDQ page. |
| FDA June 12, 2025 head-and-neck perioperative approval | Public/user-fee routes; Merck applicant data Tier 4/D, independent efficacy excluded. | United States FDA jurisdiction; Silver Spring, Maryland. | Tier 2 dated regulatory status only. | B, provisional; actual decision. Eligibility/local-access gaps; approval does not clear applicant trials. |
| Merck second-quarter 2026 financial results | Actual August 4, 2026 report documents pharmaceutical/product sales, including Keytruda/Keytruda Qlex, collaboration and investor routes. Development transactions include licensing and a Blackstone funding agreement; no exact head-and-neck trial allocation inferred. | United States; Merck & Co., Inc., Rahway, New Jersey, known as MSD outside the US/Canada. Separate from German Merck KGaA. | Tier 4 therapeutic-product seller financial self-report. | D for independence — sales and investor incentives are direct. Selected financial routes only; no company treatment outcomes adopted and complete controlling interests remain unclosed. |
| Merck August 4, 2026 SEC corporate identity filing | Registrant filing identifies New Jersey incorporation, NYSE common stock and debt securities. Product revenues are in the separate company financial row; complete beneficial ownership and application spending not audited here. | United States; 126 East Lincoln Avenue, Rahway, New Jersey 07065. Executive office is not every manufacturing site. | Tier 4 manufacturer identity disclosure held by a regulator. | D for source independence — repository hosting does not change issuer interests. Statutory disclosure helps identity checking, with ownership and site-chain limits. |
| FDA FY2026 operating plan | Actual five-page plan distinguishes public budget authority and regulated-industry user fees, including drugs/biologics. No exact application or page fee assigned. | United States; federal FDA/HHS, Silver Spring, Maryland. | Tier 3 regulator financial self-report. | B, provisional — fiscal transparency and statutory accountability; fee routes, policy priorities and page allocation remain. |
| FDA visitor and headquarters information | Official institutional location self-report; public/fee routes in separate operating-plan profile. | United States; White Oak campus, Silver Spring, Maryland. | Tier 3 regulator identity self-report. | B, provisional — actual body read; regulator location does not identify a drug manufacturing site. |
| NCI budget and appropriations, May 2026 | Congressional funding through HHS/NIH. Enacted appropriations and future requests differ; no disease-page amount assigned. | United States; NCI/NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual budget process and dated body read; fiscal accountability, budget priorities and missing page allocation. |
| NCI Gift Fund and contribution routes, August 2025 | Public gifts/Gift Fund and Breast Cancer Research Stamp route separate from Congress. Named page donors and complete accepted receipts unclosed. | United States; 9000 Rockville Pike, Bethesda, Maryland; federal NCI. | Tier 3 institutional financial self-report. | B, provisional — actual contribution and headquarters text read; no named donor control or page sponsorship inferred. |
| NCI PDQ editorial boards, November 2022 | NCI support; non-government member honoraria/travel expenses. Declarations and recusal required; specific conflicts not publicly required. | United States; NCI, Bethesda, with international board contributors. | Tier 3 institutional process and payment self-report. | B, provisional — actual dated policy read; editorial independence does not clear member interests or sponsored underlying trials. |
| NHS national content policy, October 2022 | DHSC funding; policy states no advertising or corporate sponsorship. Full page/expert receipts unclosed. | United Kingdom; national NHS website. | Tier 3 financial/editorial self-report. | B, provisional — actual funding/accuracy policy read; next review due October 2025 passed. Not a provider-trust accounts profile. |
Frequently asked questions
Is every voice-box cancer a vocal-cord cancer? No. The larynx also includes tissue above and below the true cords; the exact subsite matters. NCI anatomy.
Can laryngeal cancer be diagnosed from hoarseness alone? No. Examination and tissue sampling establish the diagnosis; persistent symptoms still need assessment. NHS investigations.
Can a neck lump establish cancer by itself? No. Tissue assessment establishes the diagnosis. NHS investigations.
Can treatment affect swallowing as well as speech? Yes. Ask about rehabilitation for both functions. NHS functional care.
Sources and funding notes
The map distinguishes source roles, conflicts and remaining gaps. Detailed subtype care and complete study payments remain unassessed.
- NCI laryngeal professional PDQ — Selected anatomy, risk, presentation and named-lead attribution.
- NCI laryngeal patient PDQ — Selected surgical roles; patient version dated February 12, 2025.
- NHS laryngeal definition — Selected actual clinical body; no outcome rates or personal regimen.
- NHS laryngeal symptoms and breathing warning — Selected actual clinical body; no outcome rates or personal regimen.
- NHS laryngeal risk explanation — Selected actual clinical body; no outcome rates or personal regimen.
- NHS laryngeal tests and next steps — Selected actual clinical body; no outcome rates or personal regimen.
- NHS laryngeal treatment and functional support — Selected actual clinical body; no outcome rates or personal regimen.
- CAP April 2026 larynx protocol v4.3 — Actual selected anatomy, contributors and AJCC 8 reporting framework.
- CUH laryngectomy stoma and voice-prosthesis leaflet — Permanent neck-airway distinction and selected communication/urgent-contact context.
- Cambridge University Hospitals 2025–26 own annual accounts — Provider-specific revenue and headquarters context only.
- CAP current protocol release register — Actual dated releases and observed protocol links only.
- CAP 2025 own annual report: selected financial tables — Institutional revenue routes only.
- CAP current contact and support — Institutional headquarters only.
- DEPEND March 6, 2025 original: protocol-author research funding — Financial-only provenance for Nicole Cipriani; clinical trial outcomes excluded.
- NCI head-and-neck cancer fact sheet — Anatomy, risk and rehabilitation context; no quantitative outcomes.
- NCI native mouth and throat side effects — Dental coordination and functional problems only; dated, no home rinse or intake protocol.
- NCI radiation side effects — Treatment-field and late-effect context.
- NCI diets and supplements — Unproved cure and treatment-compatibility boundaries.
- NCI follow-up medical care — Individual survivorship planning.
- NCI clinical-trial explanation — Human research categories and informed questions, not treatment benefit.
- NHS swallowing-problem safety — Urgent swallowing warnings and speech-and-language support; no personal intake protocol.
- NHS severe breathing warning — Selected urgent warning only; no diagnostic self-test or numerical protocol.
- Andrea Bonetti current own biography and clinical-service page — Reviewer identity, clinical employment and named research role only.
- EORTC and Menarini TREATctDNA announcement, October 19, 2023 — Dated trial drug-supply provenance only; breast-cancer treatment outcomes not used.
- EORTC institutional funding model — Research-organisation revenue routes only.
- EORTC current institutional contact — Research-organisation headquarters only.
- Menarini current headquarters and company registration — Pharmaceutical company identity only.
- Minh Tam Truong ASTRO 2024 presenter disclosure — Dated reviewer identity and activity-specific declaration only.
- ASTRO 2022 head-and-neck committee disclosures — Historical, activity-specific Truong financial declaration only.
- FDA June 12, 2025 head-and-neck perioperative approval — Selected US regulatory status only; applicant trial efficacy excluded.
- Merck second-quarter 2026 financial results — Product-seller revenue and incentives only.
- Merck August 4, 2026 SEC corporate identity filing — Corporate registration and principal executive office only.
- FDA FY2026 operating plan — Actual regulator funding route only.
- FDA visitor and headquarters information — Regulator location only.
- NCI budget and appropriations, May 2026 — Institutional appropriation route only.
- NCI Gift Fund and contribution routes, August 2025 — Separate gift route and office identity; no clinical evidence.
- NCI PDQ editorial boards, November 2022 — Board independence, honoraria and conflict-disclosure scope.
- NHS national content policy, October 2022 — Website funding and editorial safeguards only.
Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.